Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer

Yesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent dise...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Franco YL, Vaidya TR, Ait-Oudhia S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Liposomal doxorubicin Breast cancer Anti-tumor activity Cardiotoxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c2b365b508034eafa2fb3a030de4fa18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2b365b508034eafa2fb3a030de4fa18
record_format	dspace
spelling	oai:doaj.org-article:c2b365b508034eafa2fb3a030de4fa182021-12-02T09:02:07ZAnticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer1179-1314https://doaj.org/article/c2b365b508034eafa2fb3a030de4fa182018-09-01T00:00:00Zhttps://www.dovepress.com/anticancer-and-cardio-protective-effects-of-liposomal-doxorubicin-in-t-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Yesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius, is a potent chemotherapeutic drug that is successfully used to treat various forms of liquid and solid tumors and is currently approved to treat BC. DOX exerts its effects by intercalation into DNA and inhibition of topoisomerases I and II, causing damage to DNA and the formation of reactive oxygen species (ROS), resulting in the activation of caspases, which ultimately leads to apoptosis. Unfortunately, DOX also can cause cardiotoxicity, with patients only allowed a cumulative lifetime dose of 550 mg/m2. Efforts to decrease cardiotoxicity and to increase the blood circulation time of DOX led to the US Food and Drug Administration (FDA) approval of a PEGylated liposomal formulation (L-DOX), Doxil® (known internationally as Caelyx®). Both exhibit better cardiovascular safety profiles; however, they are not currently FDA approved for the treatment of metastatic BC. Here, we provide detailed insights into the mechanism of action of L-DOX and its most common side effects and highlight results of its use in clinical trials for the treatment of BC as single agent and in combination with other commonly used chemotherapeutics. Keywords: doxil, caelyx, breast cancer, anti-tumor activity, cardiotoxicityFranco YLVaidya TRAit-Oudhia SDove Medical PressarticleLiposomal doxorubicinBreast cancerAnti-tumor activityCardiotoxicityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 131-141 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Liposomal doxorubicin Breast cancer Anti-tumor activity Cardiotoxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Liposomal doxorubicin Breast cancer Anti-tumor activity Cardiotoxicity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Franco YL Vaidya TR Ait-Oudhia S Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
description	Yesenia L Franco,* Tanaya R Vaidya,* Sihem Ait-Oudhia Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL, USA *These authors contributed equally to this work Abstract: Breast cancer (BC) is a highly prevalent disease, accounting for the second highest number of cancer-related mortalities worldwide. The anthracycline doxorubicin (DOX), isolated from Streptomyces peucetius var. caesius, is a potent chemotherapeutic drug that is successfully used to treat various forms of liquid and solid tumors and is currently approved to treat BC. DOX exerts its effects by intercalation into DNA and inhibition of topoisomerases I and II, causing damage to DNA and the formation of reactive oxygen species (ROS), resulting in the activation of caspases, which ultimately leads to apoptosis. Unfortunately, DOX also can cause cardiotoxicity, with patients only allowed a cumulative lifetime dose of 550 mg/m2. Efforts to decrease cardiotoxicity and to increase the blood circulation time of DOX led to the US Food and Drug Administration (FDA) approval of a PEGylated liposomal formulation (L-DOX), Doxil® (known internationally as Caelyx®). Both exhibit better cardiovascular safety profiles; however, they are not currently FDA approved for the treatment of metastatic BC. Here, we provide detailed insights into the mechanism of action of L-DOX and its most common side effects and highlight results of its use in clinical trials for the treatment of BC as single agent and in combination with other commonly used chemotherapeutics. Keywords: doxil, caelyx, breast cancer, anti-tumor activity, cardiotoxicity
format	article
author	Franco YL Vaidya TR Ait-Oudhia S
author_facet	Franco YL Vaidya TR Ait-Oudhia S
author_sort	Franco YL
title	Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
title_short	Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
title_full	Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
title_fullStr	Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
title_full_unstemmed	Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
title_sort	anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/c2b365b508034eafa2fb3a030de4fa18
work_keys_str_mv	AT francoyl anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer AT vaidyatr anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer AT aitoudhias anticancerandcardioprotectiveeffectsofliposomaldoxorubicininthetreatmentofbreastcancer
_version_	1718398269770432512

Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer

Ejemplares similares